Skip to main content
. 2019 Nov 1;45(1):186–194. doi: 10.3892/ijmm.2019.4393

Figure 1.

Figure 1

Honokiol (Hnk) protects H9c2 cardiomyocytes against Dox-induced senescence. (A) H9c2 cardiomyocytes were pretreated with different concentrations of Hnk (0.5-10 µM) for 24 h prior to Dox (0.1 µM) exposure for 48 h, which was followed by a CCK-8 assay to evaluate cell viability. (B) Cultured H9c2 cardiomyocytes were pretreated with Hnk (0, 2.5 or 5 µM), followed by treatment with Dox (0.1 µM) for 48 h. Representative images of the co-staining for SA-β-gal-positive cells (blue; arrows). Magnification ×200. Scale bar, 50 µm. (C) Percentage of SA-β-gal-positive H9c2 cells. (D) Detection of p16INK4A and p21 protein levels. (E and F) Quantification of p16INK4A and p21 protein levels. The results are representative of at least three independent experiments. &&&P<0.001 vs. vehicle group; *P<0.05, **P<0.01, ***P<0.001 vs. Dox group. SA-β-gal, senescence-associated β-galactosidase; Dox, doxorubicin; Hnk2.5, honokiol 2.5 µM; Hnk5.0, honokiol 5 µM.